Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug safety check for tough blood cancer

NCT ID NCT03934684

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe and tolerable the drug Kyprolis is for Indian patients whose multiple myeloma has come back or stopped responding to treatment. A total of 101 adults took part, and researchers tracked side effects and how long the drug kept the cancer from getting worse. The goal was to confirm the drug's safety under real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

  • Apollo Hospital

    Hyderabad, Andhra Pradesh, 500033, India

  • Aster Medcity

    Kochi, Kerala, 682027, India

  • Cancer Institute WIA

    Chennai, Tamil Nadu, 600020, India

  • Cytecare Cancer Hospitals

    Bengaluru, Karnataka, 560064, India

  • Deenanath Mangeshkar Hospital and Research Centre

    Pune, Maharashtra, 411004, India

  • Government Medical College

    Kozhikode, Kerala, 673008, India

  • Heath Care Group Manavata Cancer Centre

    Nashik, Maharashtra, 422 004, India

  • Jawaharlal Institute of Postgraduate Medical Education and Research

    Puducherry, Puducherry, 605 006, India

  • K L E S Dr Prabhakar Kore Hospital and Medical Research Centre

    Belagavi, Karnataka, 590010, India

  • M S Ramaiah Memorial Hospital

    Bangalore, Karnataka, 560054, India

  • Mumbai Oncocare Center

    Mumbai, Maharashtra, 400 056, India

  • Navsanjeevani Hospital

    Nashik, Maharashtra, 422 002, India

  • Netaji Subhash Chandra Bose Cancer Research Institute

    Kolkata, West Bengal, 700 094, India

  • Tata Memorial Hospital

    Mumbai, Maharashtra, 400 012, India

  • Thangam Cancer Centre

    Namakkal, Tamil Nadu, 637001, India

  • Valentis Cancer Hospital

    Meerut, Uttar Pradesh, 250001, India

  • Yashoda Hospital

    Hyderabad, Andhra Pradesh, 500 082, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.